@ARTICLE{
author={Maglakelidze Marina,Ryspayeva D,Andric Zoran G,Petrovic Zeljko M,Bulat IV,Nikolic Ivan V,Chawla T,Nagarkar R,Wiedermann Ursula,Blumenstein BA,Chong LMO,Ede NJ,Nixon B,Good AJ},
year={2022},
title={HERIZON overall survival results: A study of IMU-131, a HER2 targeting peptide vaccine, plus standard of care chemotherapy in patients with HER2 overexpressing metastatic or advanced gastric/GEJ cancer},
journal={ANNALS OF ONCOLOGY},
volume={38},
number={9},
pages={S1460-S1460},
document_type={Meeting Abstract},
}